{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T17:44:47Z","timestamp":1793814287817,"version":"4.6.1"},"reference-count":20,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"unspecified","delay-in-days":22,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Miltenyi Biomedicine GmbH"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,9,23]]},"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:p>We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.<\/jats:p>","DOI":"10.1136\/rmdopen-2024-004727","type":"journal-article","created":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T02:40:18Z","timestamp":1729737618000},"page":"e004727","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5591-8975","authenticated-orcid":false,"given":"David","family":"Szabo","sequence":"first","affiliation":[{"name":"Miltenyi Biomedicine GmbH, Bergisch Gladbach, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Balogh","sequence":"additional","affiliation":[{"name":"Department of Hematology, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Gopcsa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Giba-Kiss","sequence":"additional","affiliation":[{"name":"Department of Hematology, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gergely","family":"Lakatos","sequence":"additional","affiliation":[{"name":"Department of Hematology, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Paksi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marienn","family":"Reti","sequence":"additional","affiliation":[{"name":"Department of Hematology, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Takacs","sequence":"additional","affiliation":[{"name":"Miltenyi Biomedicine GmbH, Bergisch Gladbach, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl van","family":"Heteren","sequence":"additional","affiliation":[{"name":"Miltenyi Biomedicine GmbH, Bergisch Gladbach, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Zadoyan","sequence":"additional","affiliation":[{"name":"Miltenyi Biomedicine GmbH, Bergisch Gladbach, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Holtkamp","sequence":"additional","affiliation":[{"name":"Miltenyi Biomedicine GmbH, Bergisch Gladbach, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toon","family":"Overstijns","sequence":"additional","affiliation":[{"name":"Miltenyi Biomedicine GmbH, Bergisch Gladbach, Nordrhein-Westfalen, Germany"},{"name":"Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Miltenyi","sequence":"additional","affiliation":[{"name":"Miltenyi Biomedicine GmbH, Bergisch Gladbach, Nordrhein-Westfalen, Germany"},{"name":"Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Nordrhein-Westfalen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Remenyi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Central Hospital of Southern Pest, National Institute of Hematology and Infectious Diseases, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Heart and Vascular Center, Department of Genetics, Cell and Immunobiology, Semmelweis University, Budapest, Hungary"},{"name":"National Institute of Locomotor Diseases and Disabilities, Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"2025090313032044000_10.4.e004727.1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217344"},{"key":"2025090313032044000_10.4.e004727.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220973"},{"key":"2025090313032044000_10.4.e004727.3","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0707-1","article-title":"Sustained biologic-free and drug-free remission in rheumatoid arthritis, where are we now?","volume":"17","author":"Nagy","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090313032044000_10.4.e004727.4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1556\/2068.2024.10004","article-title":"Classification and Treatment of Diffuse Large B-Cell Lymphoma","volume":"57","author":"Gergely","year":"2024","journal-title":"Hematol Transzfuziol"},{"key":"2025090313032044000_10.4.e004727.5","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-017-3414-2","article-title":"The dose-response relationship between tobacco smoking and the risk of lymphomas: a case-control study","volume":"17","author":"Taborelli","year":"2017","journal-title":"BMC Cancer"},{"key":"2025090313032044000_10.4.e004727.6","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12755"},{"key":"2025090313032044000_10.4.e004727.7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/hon.3166_OT20","article-title":"A Randomized Phase II study of MB\u2010CART2019.1 Compared To Standard of Care In Patients With Relapsed\/Refractory DLBCL Ineligible For ASCT \u2013 DALY 2\u2010EU Trial","volume":"41","author":"Borchmann","year":"2023","journal-title":"Hematol Oncol"},{"key":"2025090313032044000_10.4.e004727.8","first-page":"29","article-title":"Zamtocabtagene Autoleucel (MB-CART2019.1): An Investigational CAR-T Cell Product with Tandem Targeting of CD19 and CD20 as a Potential Treatment Option for Patients with Relapsed\/ Refractory B Cell Non-Hodgkin Lymphoma","volume":"10","author":"Borchmann","year":"2022","journal-title":"EMJ Hematol"},{"key":"2025090313032044000_10.4.e004727.9","doi-asserted-by":"crossref","first-page":"152479","DOI":"10.1016\/j.semarthrit.2024.152479","article-title":"Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions","volume":"67","author":"Ohno","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2025090313032044000_10.4.e004727.10","doi-asserted-by":"crossref","unstructured":"Haghikia A , Hegelmaier T , Wolleschak D , et al . Clinical efficacy and autoantibody seroconversion with CD19-CAR T cell therapy in a patient with rheumatoid arthritis and coexisting myasthenia gravis. Ann Rheum Dis 2024.:ard-2024-226017. doi:10.1136\/ard-2024-226017","DOI":"10.1136\/ard-2024-226017"},{"key":"2025090313032044000_10.4.e004727.11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl467"},{"key":"2025090313032044000_10.4.e004727.12","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2"},{"key":"2025090313032044000_10.4.e004727.13","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","article-title":"CD19-targeted CAR T cells in refractory antisynthetase syndrome","volume":"401","author":"M\u00fcller","year":"2023","journal-title":"Lancet"},{"key":"2025090313032044000_10.4.e004727.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2107725"},{"key":"2025090313032044000_10.4.e004727.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5"},{"key":"2025090313032044000_10.4.e004727.16","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","article-title":"Anti-CD19 CAR T cells for refractory myasthenia gravis","volume":"22","author":"Haghikia","year":"2023","journal-title":"Lancet Neurol"},{"key":"2025090313032044000_10.4.e004727.17","doi-asserted-by":"crossref","unstructured":"Bergmann C , M\u00fcller F , J\u00f6rg HWD , et al . Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis 2023;1117\u201320. doi:10.1136\/ard-2023-223952","DOI":"10.1136\/annrheumdis-2023-eular.2362"},{"key":"2025090313032044000_10.4.e004727.18","doi-asserted-by":"crossref","unstructured":"Schett G , Mielenz D , Nagy G , et al . B-cell depletion in autoimmune diseases. Ann Rheum Dis 2024.:ard-2024-225727. doi:10.1136\/ard-2024-225727","DOI":"10.1136\/ard-2024-225727"},{"key":"2025090313032044000_10.4.e004727.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2025090313032044000_10.4.e004727.20","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR T cells for treating autoimmune diseases","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004727","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:03:29Z","timestamp":1756929809000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,10,23]]},"published-print":{"date-parts":[[2024,10]]}},"alternative-id":["10.1136\/rmdopen-2024-004727"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004727","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]}}}